1500011H22Rik Inhibitors
Chemical inhibitors of the protein encoded by the gene 1500011H22Rik have been identified to function by disrupting various signaling pathways that regulate the activity of this protein. Wortmannin and LY294002 are two such inhibitors that target the phosphoinositide 3-kinases (PI3K) pathway. Wortmannin, a steroidal metabolite, acts by selectively inhibiting PI3K which leads to a reduction in AKT phosphorylation. Since the protein in question operates downstream of the PI3K/AKT pathway, the inhibition caused by Wortmannin results in a decrease in its functional activity. LY294002, a synthetic molecule, similarly inhibits PI3K, which blocks the activation of the AKT signaling pathway, thereby also leading to a suppression of the activity of this protein.
Further along the PI3K/AKT/mTOR pathway, Rapamycin interrupts the function of mTOR by binding to FKBP12, which in turn suppresses the downstream signaling involving mTOR. This suppression includes the functional activity of the protein encoded by 1500011H22Rik. In the MAPK/ERK pathway, U0126 and PD98059 target MEK1/2, inhibiting their ability to phosphorylate ERK1/2. This inhibition prevents the activation of proteins that are regulated by this pathway, including the protein of interest. SB203580 and SP600125 inhibit different kinases; SB203580 selectively inhibits p38 MAP kinase, while SP600125 inhibits JNK. Both of these inhibitors prevent the phosphorylation and activation of proteins involved in their respective MAPK pathways, leading to the functional inhibition of the protein encoded by 1500011H22Rik. Additionally, Gefitinib and Erlotinib, which are selective inhibitors of EGFR tyrosine kinase, block the signaling pathways activated by EGFR, leading to a disruption in the signaling cascade that regulates the activity of the protein in question.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal metabolite that selectively inhibits phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, Wortmannin can reduce the phosphorylation of AKT, which is a downstream target of PI3K. Given that 1500011H22Rik is involved in a signaling pathway that includes PI3K/AKT, inhibition of PI3K by Wortmannin would result in decreased AKT activity, leading to the functional inhibition of 1500011H22Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a synthetic molecule that functions as an inhibitor of PI3K. By blocking PI3K, LY294002 prevents the activation of the AKT signaling pathway. Since 1500011H22Rik operates downstream of the PI3K/AKT pathway, the inhibition of PI3K by LY294002 would suppress the activity of AKT, thereby functionally inhibiting 1500011H22Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a macrolide compound that binds to FKBP12 and inhibits mTOR, which is part of the PI3K/AKT/mTOR signaling pathway. By inhibiting mTOR activity, Rapamycin can suppress the downstream signaling that involves 1500011H22Rik. This results in the functional inhibition of 1500011H22Rik due to interruption of its signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes responsible for the phosphorylation of ERK1/2 in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK1/2 and thereby the functional activity of proteins regulated by this pathway. Since 1500011H22Rik is a downstream effector in the MAPK/ERK pathway, its function is inhibited as a result of the upstream blockade of this pathway by U0126. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a synthetic compound that specifically inhibits MEK1/2, similar to U0126. The inhibition of these kinases by PD98059 leads to the functional inhibition of the ERK1/2 signaling pathway. As 1500011H22Rik is a protein implicated in the MAPK/ERK pathway, the inhibition of this pathway by PD98059 results in the functional inhibition of 1500011H22Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that selectively inhibits p38 MAP kinase. Inhibition of p38 by SB203580 disrupts the p38 MAPK signaling pathway. As 1500011H22Rik is a protein that acts downstream in the p38 MAPK pathway, the functional inhibition of p38 by SB203580 leads to the functional inhibition of 1500011H22Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of JNK, thereby impeding the JNK signaling pathway. By inhibiting JNK, SP600125 can prevent the phosphorylation and activation of proteins that are regulated by JNK signaling. If 1500011H22Rik is involved in the JNK pathway, the inhibition of JNK by SP600125 would result in the functional inhibition of 1500011H22Rik. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a quinazoline derivative that selectively inhibits EGFR tyrosine kinase. Inhibition of EGFR by Gefitinib leads to the suppression of the EGFR signaling pathway. Since 1500011H22Rik is regulated via the EGFR pathway, the inhibition of EGFR by Gefitinib would lead to the functional inhibition of 1500011H22Rik by disrupting the signaling cascade that it is a part of. | ||||||